NICE u-turn backs NHS use of Veltassa
The drug will be funded on the NHS to treat hyperkalaemia
Read Moreby Selina McKee | Dec 16, 2019 | News | 0
The drug will be funded on the NHS to treat hyperkalaemia
Read Moreby Selina McKee | Oct 29, 2018 | News | 0
Preliminary guidelines released by the National Institute for Health and Care Excellence do not recommend NHS funding for hyperkalaemia treatments Lokelma and Veltassa.
Read Moreby Selina McKee | Aug 14, 2018 | News | 0
The Scottish Medicines Consortium has approved funding for four newly licensed medicines, expanding NHS treatments options in Scotland for ovarian cancer, lung cancer, urea cycle disorders and acute hereditary angioedema.
Read Moreby Selina McKee | Jul 21, 2017 | News | 0
European regulators have approved Vifor Pharma’s new potassium binder Veltassa to treat hyperkalaemia in adult patients.
Read Moreby Selina McKee | May 22, 2017 | News | 0
Eleven new medicines have been put forward for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use, including new options for a rare eye disease, schizophrenia and cartilage defects.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
